Oppenheimer Assumes Ionis Pharmaceuticals (IONS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Price: $44.39 -1.14%
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Oppenheimer analyst Justin Kim assumes coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Outperform rating and a price target of $59.00.
For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.
Shares of Ionis Pharmaceuticals closed at $39.31 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts Anthropic (ANT), Defers Offering Rating
- Lake Street Starts Airsculpt Technologies Inc. (AIRS) at Buy
- H.C. Wainwright Assumes Coherus Biosciences (CHRS) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
